News
PPBT
0.5900
+20.41%
0.1000
12 Health Care Stocks Moving In Monday's After-Market Session
Nuwellis (NASDAQ:NUWE) stock rose 46.8% to $0.48 during Monday's after-market session. Sensei Biotherapeutics and Cognition Therapeutics among the gainers. Losers include Phio Pharma and Rigel Pharmaceuticals.
Benzinga · 1d ago
Weekly Report: what happened at PPBT last week (0415-0419)?
Weekly Report · 2d ago
Weekly Report: what happened at PPBT last week (0408-0412)?
Weekly Report · 04/15 09:42
Weekly Report: what happened at PPBT last week (0401-0405)?
Weekly Report · 04/08 09:44
Weekly Report: what happened at PPBT last week (0325-0329)?
Weekly Report · 04/01 09:44
Purple Biotech’s NT219 Shows Promising Cancer Fight
TipRanks · 03/28 11:59
Weekly Report: what happened at PPBT last week (0318-0322)?
Weekly Report · 03/25 09:45
Weekly Report: what happened at PPBT last week (0311-0315)?
Weekly Report · 03/18 09:44
Purple Biotech Reports Preclinical Proof of Concept for its Tribody Platform Technology
Barchart · 03/14 06:30
Weekly Report: what happened at PPBT last week (0304-0308)?
Weekly Report · 03/11 09:43
Purple Biotech Price Target Maintained With a $11.00/Share by Chardan Capital
Dow Jones · 03/07 19:05
Purple Biotech Is Maintained at Buy by Chardan Capital
Dow Jones · 03/07 19:05
Chardan Capital Maintains Buy on Purple Biotech, Maintains $11 Price Target
Benzinga · 03/07 18:56
PPBT Stock Earnings: Purple Biotech Meets EPS for Q4 2023
Purple Biotech reported earnings per share of -19 cents. The company did not report any revenue for the quarter. Purple Biotech met the analyst estimate for EPS of -18 cents. The company is not expected to report any earnings for the second quarter of 2014.
Investorplace · 03/06 04:52
Purple Biotech Price Target Maintained With a $10.00/Share by HC Wainwright & Co.
Dow Jones · 03/05 17:17
HC Wainwright & Co. Reiterates Buy on Purple Biotech, Maintains $10 Price Target
Benzinga · 03/05 17:07
Promising Pipeline Prospects for Purple Biotech: Buy Rating Affirmed Amidst Anticipated Clinical Advancements
TipRanks · 03/05 16:35
Purple Biotech Q4 EPS $(0.19), Inline
Benzinga · 03/05 12:58
Purple Biotech Reports Fourth Quarter and Full-Year 2023 Financial Results
Purple Biotech Ltd. Announced financial results for the fourth quarter and full year ended December 31, 2023. The company is developing first-in-class therapies that harness the power of the tumor microenvironment to overcome tumor immune evasion and drug resistance. Purple Biotech is a clinical-stage company.
Barchart · 03/05 06:55
Weekly Report: what happened at PPBT last week (0226-0301)?
Weekly Report · 03/04 09:44
More
Webull provides a variety of real-time PPBT stock news. You can receive the latest news about Purple Biotech Ltd through multiple platforms. This information may help you make smarter investment decisions.
About PPBT
Purple Biotech Ltd, formerly Kitov Pharma Ltd, is an Israel-based clinical-stage company that develops drugs that overcome tumor-immune evasion and drug resistancetreat pain. Main products of the Company is NT-219 i CM-24. CM-24 is a monoclonal antibody blockin and NT-219 is a small molecule bi-specific inhibitor of two key cancer resistance pathways. The Company is also the owner of Consensi, a fixed-dose combination of celecoxib and amlodipine besylate, for the simultaneous treatment of osteoarthritis pain and hypertension.